Nahata M C, Barson W J
Drug Intell Clin Pharm. 1985 Dec;19(12):900-6. doi: 10.1177/106002808501901203.
Ceftriaxone is a new third-generation cephalosporin with excellent activity against many gram-negative, and reasonable activity against most gram-positive microorganisms. Clinical studies have demonstrated its efficacy and safety in patients with bacterial meningitis; respiratory tract, urinary tract, soft tissue, bone and joint infections; and gonorrhea. Ceftriaxone has been well tolerated except for diarrhea, which in most cases has not required a change in therapy. The long elimination half-life of ceftriaxone has allowed twice- and once-daily administration, the latter potentially resulting in substantial cost savings. Because of its documented efficacy, safety, and convenient dosing schedule, ceftriaxone may become the preferred third-generation cephalosporin for the treatment of a variety of serious infections.
头孢曲松是一种新型第三代头孢菌素，对许多革兰氏阴性菌具有优异活性，对大多数革兰氏阳性微生物也有合理活性。临床研究已证明其在细菌性脑膜炎患者、呼吸道感染、尿路感染、软组织感染、骨和关节感染以及淋病患者中的疗效和安全性。除腹泻外，头孢曲松耐受性良好，大多数情况下腹泻并不需要改变治疗方案。头孢曲松的消除半衰期较长，允许每日给药两次和一次，后者可能大幅节省成本。由于其已证明的疗效、安全性和方便的给药方案，头孢曲松可能成为治疗各种严重感染的首选第三代头孢菌素。
